02 October 2020: Clinical Research
Sodium-Glucose Cotransporter-2 Inhibitor Immediately Decreases Serum Uric Acid Levels in Type 2 Diabetic Patients
Naro Ohashi 1ABCDEF* , Taro Aoki 1BCE , Takashi Matsuyama 1BCE , Sayaka Ishigaki 2BCE , Shinsuke Isobe 1BCE , Tomoyuki Fujikura 1A , Takuya Hashimoto 3ABDE , Daisuke Tsuriya 3ABDE , Hiroshi Morita 3ABDE , Akihiko Kato 2AD , Hideo Yasuda 1ACDEDOI: 10.12659/MSM.926086
Med Sci Monit 2020; 26:e926086
Table 1 Patient characteristics.
| Age (year) | 63.7±12.7 |
| Sex | Male 14/Female 10 |
| Diabetic mellitus duration (year) | 14.0±6.1 |
| Stage of diabetic kidney disease | Stage 1: 9/Stage 2: 9/Stage 3: 6 |
| Height (cm) | 160.9±10.0 |
| Body weight (kg) | 70.6±12.7 |
| Body mass index (kg/m) | 27.1±4.2 |
| Systolic blood pressure (mmHg) | 134.9±12.5 |
| Diastolic blood pressure (mmHg) | 74.6±11.9 |
| Heart rate (/min) | 78.3±11.2 |
| Hemoglobin A1c (%) | 8.24±1.26 |
| Creatinine (mg/dL) | 0.97±0.40 |
| eGFR (mL/min/1.73 m) | 63.3±24.7 |
| Urinary albumin/creatinine (mg/g) | 33.6 [19.2–375.3] |
| Urinary protein/creatinine (g/g) | 0.096 [0.067–0.41] |
| Antihypertensive drugs usage | 15 (62.5%) |
| Antihyperlipidemic drugs usage | 14 (58.3%) |
| Antihyperuricemic drugs usage | 4 (20.0%) |
| Antidiabetic drugs usage | 24 (100%) |
| Insulin: 11 (45.8%), GLP-1 receptor agonist: 4 (16.6%), | |
| Biguanide: 14 (58.3%), Thiazolidinedione: 3 (12.5%), | |
| Sulfonylurea: 4 (16.7%), DPP-4 inhibitor: 14 (58.3%), a-glucosidase inhibitor: 4 (16.7%), Glinide: 1 (4.2%) | |
| eGFR – estimated glomerular filtration rate; DPP-4 – dipeptidyl peptidase-4; GLP-1 – glucagon-like peptide-1. | |